Kathy Mayo
Psychiatry · Greenville, NCNPI 1548372949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 841 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 31.4% of the total. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 841 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$989
- Otsuka America Pharmaceutical, Inc.$939
- Lundbeck LLC$852
- Vanda Pharmaceuticals Inc.$846
- Neurocrine Biosciences, Inc.$636
- plus $5K from 25 others
What the payments were for
- Food & beverage$13,62199%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 327 | $4,308 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 44 | $989 |
| Otsuka America Pharmaceutical, Inc. | 53 | $939 |
| Lundbeck LLC | 49 | $852 |
| Vanda Pharmaceuticals Inc. | 45 | $846 |
| Neurocrine Biosciences, Inc. | 25 | $636 |
| Alkermes, Inc. | 26 | $538 |
| Johnson & Johnson | 21 | $447 |
| Supernus Pharmaceuticals, Inc. | 35 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $424 |
| Axsome Therapeutics, Inc. | 23 | $414 |
| Sunovion Pharmaceuticals Inc. | 20 | $374 |
| Teva Pharmaceuticals USA, Inc. | 16 | $322 |
| Merck | 20 | $296 |
| Eisai Inc. | 20 | $281 |
| Corium, LLC | 13 | $280 |
| Idorsia Pharmaceuticals US Inc | 18 | $259 |
| Bausch Health US, LLC | 12 | $238 |
| Neos Therapeutics, LP | 12 | $214 |
| Jazz Pharmaceuticals Inc. | 10 | $200 |
| Adlon Therapeutics L.p. | 6 | $108 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Shire North American Group Inc | 3 | $43 |
| Almatica Pharma LLC | 3 | $41 |
| Brainsway USA Inc | 2 | $39 |
| Tris Pharma Inc | 2 | $38 |
| OWP Pharmaceuticals, Inc. | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| Biogen | 1 | $23 |
| Neuronetics, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,733 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $122,579 |
| RexultiBrexpiprazole | 41 | $81,375 |
| VraylarCariprazine Hcl | 16 | $25,798 |
| SeroquelQuetiapine Fumarate | 23 | $13,004 |
| TrintellixVortioxetine Hydrobromide | 21 | $10,397 |
| Lamictal OdtLamotrigine | 12 | $10,354 |
| Wellbutrin SrBupropion Hcl | 12 | $10,207 |
| Aripiprazole | 94 | $4,596 |
| LithobidLithium Carbonate | 11 | $3,957 |
| Bupropion XlBupropion Hcl | 152 | $2,857 |
| Duloxetine Hcl | 161 | $2,578 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 87 | $2,543 |
| Trazodone Hcl | 252 | $2,414 |
| Quetiapine Fumarate | 190 | $1,804 |
| Escitalopram Oxalate | 188 | $1,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $636 | $122,57913 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $939 | $81,37541 claims |
| AbbVieVraylar | $4,308 | $25,79816 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $424 | $10,39721 claims |
| Almatica Pharma LLCSertraline Hcl | $41 | $1,022125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Greenville
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
- David JoyeAlbemarle$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.